us
regulatori
system
permit
expand
access
compassion
use
investig
drug
outsid
clinic
trial
treat
patient
seriou
immedi
lifethreaten
diseas
condit
compar
satisfactori
altern
treatment
option
access
unapprov
intervent
circumst
may
occur
emerg
use
investig
new
drug
ind
applic
treatment
use
ind
applic
us
emerg
use
defin
use
investig
drug
biolog
product
human
subject
lifethreaten
situat
standard
accept
treatment
avail
suffici
time
obtain
institut
research
board
irb
approv
emerg
use
ind
mechan
allow
fda
author
use
experiment
drug
emerg
situat
allow
time
submiss
ind
applic
accord
standard
regul
mechan
also
use
instanc
patient
meet
criteria
exist
studi
protocol
approv
studi
protocol
exist
mechan
exempt
use
experiment
intervent
prior
irb
review
approv
provid
emerg
use
report
irb
within
five
work
day
use
mechan
allow
one
emerg
use
experiment
intervent
institut
subsequ
use
investig
product
institut
subject
prospect
irb
review
approv
use
mechan
invalu
timesensit
emerg
ebola
outbreak
like
regulatori
mechan
utilis
provid
investig
drug
zmapp
two
ebolainfect
american
liberia
us
emerg
use
ind
mechan
gener
use
emerg
situat
individu
patient
howev
mechan
illsuit
use
mass
public
health
exampl
univers
vaccin
campaign
lifethreaten
infecti
diseas
take
place
context
nation
emerg
potenti
nation
emerg
manag
instanc
us
establish
regulatori
mechan
permit
fda
approv
emerg
use
drug
devic
medic
product
includ
diagnost
previous
approv
clear
licens
fda
offlabel
use
approv
product
certain
welldefin
emerg
situat
authoris
issu
adequ
approv
avail
altern
emerg
use
product
question
exist
diseas
condit
deem
seriou
lifethreaten
total
scientif
evid
reason
indic
product
question
may
effect
known
potenti
benefit
product
outweigh
known
potenti
risk
order
issu
emerg
use
oseltamivir
tamiflu
zanamivir
relenza
peramivir
treatment
prophylaxi
influenza
viru
similarli
emerg
use
author
eua
issu
emerg
use
unapprov
anthrax
vaccin
prevent
inhal
anthrax
believ
us
militari
forc
face
heighten
risk
attack
anthrax
eua
also
previous
use
context
potenti
emerg
authoris
experiment
diagnost
coronaviru
influenza
authoris
could
deem
ethic
permiss
utilitarian
public
health
ethic
ground
valu
mechan
context
ebola
diagnost
underscor
august
follow
earlier
determin
us
secretari
homeland
secur
ebola
viru
present
materi
threat
us
popul
suffici
affect
nation
secur
august
us
secretari
health
human
servic
declar
circumst
exist
justifi
author
emerg
use
vitro
diagnost
detect
ebola
viru
basi
decis
august
us
fda
commission
issu
eua
us
depart
defens
dod
ebola
zair
target
realtim
revers
transcript
pcr
rtpcr
assay
presumpt
detect
ebola
zair
viru
offlabel
use
approv
drug
equival
research
investig
experiment
treatment
despit
use
approv
drug
unind
use
common
necessari
practic
set
practic
formal
regul
formal
condon
mani
set
us
fda
howev
attempt
clarifi
legitimaci
practic
explicitli
condon
use
approv
drug
unind
use
prescrib
circumst
fda
note
drug
product
approv
market
physician
may
prescrib
use
treatment
regimen
patient
popul
includ
approv
label
unapprov
unlabel
use
may
appropri
ration
certain
circumst
given
regulatori
permiss
us
scientist
postul
use
drug
alreadi
approv
treatment
diseas
treatment
ebola
argu
unlik
experiment
ebola
treatment
immunomodulatori
drug
alreadi
approv
thu
obviat
need
safeti
studi
current
produc
inexpens
gener
avail
even
countri
basic
health
care
system
propos
yet
win
endors
illustr
valu
regulatori
regim
permit
offlabel
clinic
use
outsid
eua
direct
approach
may
allow
use
antiinfluenza
drug
favipiravir
emerg
offlabel
antiebola
agent
current
case
franc
notwithstand
plan
test
antiebola
agent
clinic
trial
condit
us
regulatori
system
permit
partial
lift
suspend
halt
clinic
trial
instanc
fda
discret
partial
lift
trial
previous
declar
hold
prescrib
circumst
mechan
avoid
allornoth
approach
permit
clinic
trial
investig
agent
proceed
prescrib
condit
invalu
context
timesensit
public
health
emerg
util
mechan
best
illustr
relat
clinic
trial
antiebola
investig
drug
tkmebola
drug
approv
test
phase
clinic
trial
trial
put
hold
earli
juli
investig
mechan
behind
elev
cytokin
healthi
human
volunt
receiv
drug
fda
chang
statu
drug
trial
partial
hold
august
open
possibl
administr
ebolainfect
patient
singl
ascend
dose
drug
demonstr
toler
absenc
steroidcontain
premed
dose
level
mgkg
maximum
toler
dose
absenc
steroid
cover
us
fda
author
permit
use
drug
product
instanc
human
efficaci
studi
ethic
feasibl
grant
authoris
fda
may
grant
market
approv
new
drug
product
safeti
establish
base
adequ
wellcontrol
anim
studi
result
anim
studi
establish
drug
product
reason
like
produc
clinic
benefit
human
assess
adequaci
anim
data
fda
may
take
account
data
includ
avail
human
data
mechan
allow
fda
approv
drug
base
efficaci
test
anim
safeti
test
healthi
human
mechan
particularli
valuabl
context
public
health
emerg
follow
tradit
phase
clinic
trial
evalu
process
drug
prescrib
human
impract
unfeas
fda
use
anim
rule
mechan
approv
raxibacumab
inject
treatment
inhal
anthrax
regulatori
mechan
postul
use
context
ebola
outbreak
find
applic
respect
investig
agent
demonstr
postexposur
efficaci
ebola
viru
marburg
viru
diseas
rodent
model
soon
subject
dose
rang
efficaci
studi
nonhuman
primat
avarec
pledg
collabor
mechan
fast
track
approv
clinic
trial
registr
trial
product
african
countri
welcom
current
rapidrespons
govern
framework
employ
unapprov
intervent
humanitarian
context
global
level
system
creat
matter
urgenc
crucial
system
develop
harmon
data
requir
allow
collect
interpret
data
howev
timesensit
access
unapprov
experiment
intervent
permit
humanitarian
ground
patient
commun
face
death
irrevers
diseas
progress
efficaci
diagnost
prevent
therapeut
altern
exist
access
underpin
robust
monitor
evalu
compon
inform
product
develop
licensur
establish
govern
system
access
unregist
investig
intervent
intern
region
nation
level
crucial
manag
public
health
emerg
intern
concern
system
impot
absenc
compet
local
regulatori
capac
relev
health
system
infrastructur
adequ
train
occup
protect
research
health
worker
grassroot
level
uniform
import
export
regul
well
civil
aviat
clearanc
certif
requir
particular
attent
relat
transport
biolog
specimen
especi
countri
less
resourc
may
lack
robust
mechan
address
gap
ebolaaffect
countri
concurr
intervent
provis
entail
immers
involv
intern
agenc
unmeer
initi
avarec
donor
countri
nongovernment
organis
san
msf
serv
de
facto
primari
servic
provid
humanitarian
set
erad
ebola
necessit
intens
region
cooper
wellconsid
systemat
introduct
experiment
intervent
affect
countri
part
intern
commun
clinic
trial
antiebola
agent
offer
trial
particip
possibl
access
unapprov
intervent
howev
access
rais
ethic
issu
introduct
novel
intervent
affect
countri
requir
transpar
site
select
polici
ensur
potenti
harm
benefit
could
aris
introduct
novel
intervent
fairli
distribut
affect
countri
transpar
site
select
polici
facilit
time
prospect
commun
engag
critic
set
local
distrust
author
western
medicin
author
investig
need
ensur
relev
logist
support
infrastructur
capac
exist
propos
host
set
factor
crucial
rollout
success
ensur
integr
emerg
efficaci
data
investig
must
ensur
meaning
local
scientif
collabor
investig
author
must
appli
mind
suppli
chain
logist
clinic
support
social
support
accord
human
right
ethic
norm
solicit
inform
consent
relat
use
unproven
intervent
individu
given
particular
attent
end
investig
give
thought
manag
instanc
elig
patient
lack
abil
provid
inform
consent
autonom
qualifi
surrog
decisionmak
voluntari
may
vitiat
patient
dire
circumst
mitig
occurr
therapeut
prevent
misconcept
regard
experiment
intervent
timesensit
access
unapprov
experiment
intervent
permit
condit
humanitarian
ground
regulatori
deficit
could
stymi
timesensit
effort
contain
public
health
threat
efficaci
cur
therapeut
prevent
intervent
exist
counter
threat
question
globallevel
rapidrespons
govern
framework
employ
unapprov
intervent
humanitarian
context
establish
matter
urgenc
enact
measur
better
prepar
us
tackl
public
health
emerg
intern
concern
futur
